

Maria Luisa Gasparri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6932889/publications.pdf>

Version: 2024-02-01

89
papers

2,167
citations

236612

25
h-index

264894

42
g-index

90
all docs

90
docs citations

90
times ranked

3015
citing authors

#	ARTICLE	IF	CITATIONS
1	Endometrial Cancer and BRCA Mutations: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 3114.	1.0	5
2	Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. <i>British Journal of Surgery</i> , 2022, 109, 857-863.	0.1	22
3	What we learned in axillary management of breast cancer patients at the American society of clinical oncology (ASCO) 2020 virtual meeting? The EUBREAST point of view. <i>EClinicalMedicine</i> , 2021, 31, 100708.	3.2	0
4	Computed Tomography Based Radiomics as a Predictor of Survival in Ovarian Cancer Patients: A Systematic Review. <i>Cancers</i> , 2021, 13, 573.	1.7	24
5	The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis. <i>Cancers</i> , 2021, 13, 1391.	1.7	9
6	Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. <i>Cancers</i> , 2021, 13, 1565.	1.7	85
7	Fibrin Sealants and Axillary Lymphatic Morbidity: A Systematic Review and Meta-Analysis of 23 Clinical Randomized Trials. <i>Cancers</i> , 2021, 13, 2056.	1.7	4
8	PET/MRI for Staging the Axilla in Breast Cancer: Current Evidence and the Rationale for SNB vs. PET/MRI Trials. <i>Cancers</i> , 2021, 13, 3571.	1.7	10
9	Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis. <i>Breast</i> , 2021, 60, 155-162.	0.9	8
10	Factors predicting morbidity in surgically-staged high-risk endometrial cancer patients. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 266, 169-174.	0.5	3
11	Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patients. <i>Breast</i> , 2021, 60, 131-137.	0.9	9
12	Biological Impact of Unilateral Oophorectomy: Does the Number of Ovaries Really Matter?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 331-338.	0.8	9
13	Minimally invasive surgery does not impair overall survival in stage IIIC endometrial cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 585-590.	0.8	11
14	Sentinel lymph node intraoperative analysis in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3199-3205.	1.2	4
15	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2020, 87, 102040.	3.4	35
16	Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). <i>Breast</i> , 2020, 52, 110-115.	0.9	63
17	Unilateral versus bilateral lymph-nodal metastases and oncologic outcome in vulvar cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1877-1881.	1.2	8
18	Applications in Gynecology. , 2020, , 259-271.		0

#	ARTICLE	IF	CITATIONS
19	Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm. <i>Medicina (Lithuania)</i> , 2019, 55, 415.	0.8	14
20	Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. <i>Journal of Clinical Medicine</i> , 2019, 8, 380.	1.0	25
21	SLN mapping in early-stage cervical cancer as a minimal-invasive triaging tool for multimodal treatment. <i>European Journal of Surgical Oncology</i> , 2019, 45, 679-683.	0.5	11
22	Surgical staging in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 213-221.	1.2	19
23	Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its Partners to Overcome Metastasis and Drug Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 283-292.	0.8	17
24	Rare sites of breast cancer metastasis: a review. <i>Translational Cancer Research</i> , 2019, 8, S518-S552.	0.4	16
25	Conventional versus Single Port Laparoscopy for the Surgical Treatment of Ectopic Pregnancy: A Meta-Analysis. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 329-337.	0.7	18
26	Retrospective validation of the laparoscopic ICG SLN mapping in patients with grade 3 endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1385-1393.	1.2	33
27	Placenta previa and placental abruption after assisted reproductive technology in patients with endometriosis: a systematic review and meta-analysis. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 27-34.	0.8	32
28	Real-Time Fluorescent Sentinel Lymph Node Mapping with Indocyanine Green in Women with Previous Conization Undergoing Laparoscopic Surgery for Early Invasive Cervical Cancer: Comparison with Radiotracer-Blue Dye. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 455-460.	0.3	22
29	Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. <i>Biotechnology Advances</i> , 2018, 36, 328-334.	6.0	239
30	Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. <i>BioMed Research International</i> , 2018, 2018, 1-2.	0.9	0
31	The impact of different doses of indocyanine green on the sentinel lymph-node mapping in early stage endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2187-2191.	1.2	23
32	Misoprostol vaginal insert versus misoprostol vaginal tablets for the induction of labour: a cohort study. <i>BMC Pregnancy and Childbirth</i> , 2018, 18, 149.	0.9	20
33	Instead of feeling blue, go green!. <i>Lancet Oncology</i> , The, 2018, 19, 1273-1274.	5.1	4
34	MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2313-2318.	1.2	33
35	Obstetric complications after laparoscopic excision of posterior deep infiltrating endometriosis: a case-control study. <i>Fertility and Sterility</i> , 2018, 110, 459-466.	0.5	52
36	Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy. <i>Gynecologic Oncology</i> , 2018, 150, 261-266.	0.6	42

#	ARTICLE	IF	CITATIONS
37	Current Knowledge of miRNAs as Biomarkers in Breast Cancer. , 2018, , 221-231.		2
38	Cervical length after cerclage: comparison between laparoscopic and vaginal approach. Archives of Gynecology and Obstetrics, 2017, 295, 885-890.	0.8	11
39	Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer. Tumor Biology, 2017, 39, 101042831769552.	0.8	43
40	Indocyanine Green versus Radiotracer with or without Blue Dye for Sentinel Lymph Node Mapping in Stage >IB1 Cervical Cancer (>2Âcm). Journal of Minimally Invasive Gynecology, 2017, 24, 954-959.	0.3	39
41	Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2039-2048.	1.2	56
42	The Efficacy of Fibrin Sealant Patches in Reducing the Incidence of Lymphatic Morbidity After Radical Lymphadenectomy: A Meta-Analysis. International Journal of Gynecological Cancer, 2017, 27, 1283-1292.	1.2	21
43	PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1095-1103.	0.8	99
44	The combination of preoperative PET/CT and sentinel lymph node biopsy in the surgical management of early-stage cervical cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2275-2281.	1.2	14
45	Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye. Journal of Cancer Research and Clinical Oncology, 2017, 143, 475-480.	1.2	70
46	FIGO stage IIIC endometrial cancer identification among patients with complex atypical hyperplasia, grade 1 and 2 endometrioid endometrial cancer: laparoscopic indocyanine green sentinel lymph node mapping versus frozen section of the uterus, why get around the problem?. Journal of Cancer Research and Clinical Oncology, 2017, 143, 491-497.	1.2	30
47	Are allergic reactions to indocyanine green really that uncommon? A single institution experiences. Obstetrics and Gynecology Reports, 2017, 1, .	0.2	6
48	Is it time to consider the sentinel lymph node mapping the new standard in endometrial cancer?. Translational Cancer Research, 2017, 6, S547-S552.	0.4	4
49	PET/CT guided surgical excision of small abdominal wall metastases in morbidly obese endometrial cancer patients. Minerva Obstetrics and Gynecology, 2017, 69, 206-207.	0.5	1
50	From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach. Annals of Surgical Oncology, 2016, 23, 2959-2965.	0.7	61
51	Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyesâ€”A Meta-Analysis. Annals of Surgical Oncology, 2016, 23, 3749-3756.	0.7	150
52	Self-responsibility for Our Good Health. JAMA Oncology, 2016, 2, 1242.	3.4	0
53	The CORONIS trial on caesarean section. Lancet, The, 2016, 388, 1373.	6.3	1
54	Endometrial and cervical cancer patients with multiple sentinel lymph nodes at laparoscopic ICG mapping: How many are enough?. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1831-1836.	1.2	29

#	ARTICLE	IF	CITATIONS
55	Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology?. <i>Chemical Biology and Drug Design</i> , 2016, 87, 321-334.	1.5	31
56	Cediranib in ovarian cancer: state of the art and future perspectives. <i>Tumor Biology</i> , 2016, 37, 2833-2839.	0.8	16
57	Accuracy of Sentinel Lymph Node Mapping After Previous Hysterectomy in Patients with Occult Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2199-2205.	0.7	7
58	Laparoscopic Indocyanine Green Sentinel Lymph Node Mapping in Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2206-2211.	0.7	73
59	Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1509-1520.	1.2	20
60	Type B versus Type C Radical Hysterectomy After Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma: A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 2176-2182.	0.7	13
61	Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer. <i>Tumor Biology</i> , 2016, 37, 71-75.	0.8	25
62	Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials. <i>Oncotarget</i> , 2016, 7, 13221-13227.	0.8	21
63	Oleuropein Mediated Targeting of Signaling Network in Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2016, 16, 2477-2483.	1.0	23
64	Thrombotic thrombocytopenic purpura during pregnancy versus imitator of preeclampsia. <i>Transfusion</i> , 2015, 55, 2516-2518.	0.8	6
65	Primary chemotherapy versus primary surgery for ovarian cancer. <i>Lancet, The</i> , 2015, 386, 2142-2143.	6.3	5
66	Doppler Ultrasound Flow Evaluation of the Uterine Arteries Significantly Correlates with Tumor Size in Cervical Cancer Patients. <i>Annals of Surgical Oncology</i> , 2015, 22, 959-963.	0.7	12
67	Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift. <i>Annals of Surgical Oncology</i> , 2015, 22, 4204-4210.	0.7	41
68	Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386). <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 302-310.	2.0	16
69	When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 944-951.	0.7	13
70	Tumor Infiltrating Lymphocytes in Ovarian Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3635-3638.	0.5	37
71	Laparotomic Myomectomy in the 16th Week of Pregnancy: A Case Report. <i>Case Reports in Obstetrics and Gynecology</i> , 2014, 2014, 1-5.	0.2	13
72	Effects of unilateral ovariectomy on female fertility outcome. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 349-353.	0.8	26

#	ARTICLE	IF	CITATIONS
73	Dealing Naturally with Stumbling Blocks on Highways and Byways of TRAIL Induced Signaling. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8041-8046.	0.5	4
74	Anticancer Activity of Essential Oils: Targeting of Protein Networks in Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8047-8050.	0.5	9
75	Drugs from Marine Sources: Modulation of TRAIL Induced Apoptosis in Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9045-9047.	0.5	1
76	Ovarian Cancer: Interplay of Vitamin D Signaling and miRNA Action. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3359-3362.	0.5	8
77	Surgical treatment of an isolated omental cervical cancer recurrence: report of a case and review of the literature. Tumori, 2014, 100, e52-4.	0.6	0
78	Minimal invasive approaches for large ovarian cysts: a careful choice. Archives of Gynecology and Obstetrics, 2013, 287, 615-616.	0.8	1
79	Interaction between treg cells and angiogenesis: A dark double track. International Journal of Cancer, 2013, 132, 2469-2469.	2.3	6
80	Monoclonal antibodies therapies for ovarian cancer. Expert Opinion on Biological Therapy, 2013, 13, 739-764.	1.4	21
81	Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies. Current Molecular Medicine, 2013, 13, 648-669.	0.6	13
82	First case of isolated vaginal metastasis from breast cancer treated by surgery. BMC Cancer, 2012, 12, 479.	1.1	6
83	Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1575-1584.	1.9	30
84	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. Critical Reviews in Oncology/Hematology, 2012, 83, 35-46.	2.0	27
85	Is There a Real Standard For Stage IVa Cervical Cancer?. Gynecologic Oncology, 2011, 123, 174-175.	0.6	5
86	Letâ€™s Think Twice Before Abandoning Fibrillar Oxidized Regenerated Cellulose. Annals of Surgical Oncology, 2011, 18, 292-293.	0.7	2
87	Vaginal Reconstruction with the Abbâ€™-McIndoe Technique: From Dermal Grafts to Autologous in Vitro Cultured Vaginal Tissue Transplant. Seminars in Reproductive Medicine, 2011, 29, 045-054.	0.5	25
88	Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View. Clinical and Developmental Immunology, 2011, 2011, 1-16.	3.3	38
89	Immunologic Systemic Effect of Neoadjuvant Chemotherapy Requires Investigation Before Tumor-Associated Lymphocytes Can Be Introduced in Breast Cancer Treatment Algorithm. Journal of Clinical Oncology, 2010, 28, e471-e472.	0.8	7